Antimalarial therapy: a panacea for mild lupus?

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Antimalarial drugs have a proven history in managing mild Systemic Lupus Erythematosus (SLE).
• Hydroxychloroquine, with or without mepacrine, offers medium to long-term benefits for lupus patients.
• Updated monitoring guidelines for hydroxychloroquine have decreased the necessity for frequent visual examinations.

Purpose of the Study:

• To review the efficacy and benefits of antimalarial therapy in mild SLE.
• To highlight the role of hydroxychloroquine in lupus management.
• To emphasize the broader metabolic and anticoagulant effects of antimalarials.

Main Methods:

• Literature review of antimalarial use in SLE.
• Analysis of clinical outcomes associated with hydroxychloroquine and mepacrine.
• Examination of recent guideline changes for hydroxychloroquine monitoring.

Main Results:

• Antimalarial therapy, particularly hydroxychloroquine, ameliorates lupus symptoms.
• Consistent use of antimalarials can decrease the rate of SLE relapses.
• Antimalarials provide additional benefits including improved lipid and glucose metabolism and weak anticoagulant activity.

Conclusions:

• Antimalarial drugs are a recommended treatment for most patients with mild SLE.
• Hydroxychloroquine is a cornerstone therapy for mild lupus, offering symptomatic relief and disease control.
• The favorable safety profile and additional metabolic benefits support the consideration of antimalarials in SLE management.